What is the clinical evidence from this study?

Study design: Observational. Population: Echovirus 30 (E30) infection (n=4537). Intervention: Echovirus 30 (E30) infection upsurge vs. 2015-2017 baseline data. Primary outcome: Number of E30 detections and clinical presentation.

November 1, 2018EurosurveillanceOpen Access

Upsurge in echovirus 30 detections in five EU/EEA countries, April to September, 2018

View Full Paper

Ask AI

Bookmark

Key result

An upsurge in Echovirus 30 infections was observed in five EU/EEA countries between April and September 2018, with 658 cases detected primarily in newborns and adults aged 26-45 years, often presenting with CNS symptoms.

Population

4,537 patients with enterovirus infections detected in 15 EU/EEA countries between January and September…

Authors

EBEeva BrobergEuropean Centre for Disease Prevention and Control BSBenedetto SimoneUniversity of Salerno JJJ.M. JansàUniversitat Autònoma de Barcelona

Discussion

Member takes

Implication

Clinicians should heighten enterovirus surveillance in neonates and adults with CNS symptoms; leaves open outbreak drivers and strain evolution.

Study Design

Type

Observational (n=4,537)

Multicenter

Yes

Structured PICO

Population

4,537 enterovirus-positive patients, including 658 with Echovirus 30 infections, reported across 15 EU/EEA countries between January and September 2018, primarily affecting newborns and adults aged 26-45 years.

Outcome

Number of Echovirus 30 (E30) detections and associated demographic and clinical characteristics

An upsurge in Echovirus 30 infections, frequently associated with meningitis and meningoencephalitis, was detected across several European countries in 2018, highlighting the need for continued public health vigilance.

Limitations

Enterovirus surveillance is mainly passive and captures primarily severe cases.
Only 15 EU/EEA countries took part, so data are not representative for the whole region.
Data from some countries were not from all parts or not representative of the entire population.
Level of testing and methods used for diagnostics and typing vary between countries.
Some E30 results may have been missed with the regularly used VP1 sequence typing protocol due to low viral load.
Typing data were still pending for August and September.
Data were collected in aggregate format, limiting further analysis.
Longer data series would have been beneficial to assess the extent of the upsurge.
Enterovirus surveillance is mainly passive and captures primarily severe cases rather than mild diseases.
Only 15 EU/EEA countries took part, so data are not representative for the whole EU/EEA region.
Data were collected in aggregate format, preventing further analysis on specific age groups, clinical symptoms, or sex ratio.

Cite This Study

Broberg et al. (2018) conducted an observational in Echovirus 30 (E30) infection (n=4,537). Echovirus 30 (E30) infection upsurge vs. 2015-2017 baseline data was evaluated on Number of E30 detections and clinical presentation. An upsurge in Echovirus 30 infections was observed in five EU/EEA countries between April and September 2018, with 658 cases detected primarily in newborns and adults aged 26-45 years, often presenting with CNS symptoms.

synapsesocial.com/papers/6a900efae8d327d500340d8c https://doi.org/10.2807/1560-7917.es.2018.23.44.1800537

View Full Paper

Ask AI

Bookmark

Implication

Clinicians should heighten enterovirus surveillance in neonates and adults with CNS symptoms; leaves open outbreak drivers and strain evolution.

Upsurge in echovirus 30 detections in five EU/EEA countries, April to September, 2018

Discussion

Member takes

Implication

Study Design

Structured PICO

Limitations

Cite This Study

Upsurge in echovirus 30 detections in five EU/EEA countries, April to September, 2018

Discussion

Member takes

Implication

Study Design

Structured PICO

Limitations

Cite This Study

Also Consider

Also Consider